It was a pleasure to speak with Dr Rick Adachi (McMaster University, St. Joseph’s Healthcare, Hamilton, Ontario, Canada) around his post-hoc subgroup analysis of denosumab vs risedronate in the treatment of glucocorticoid-induced osteoporosis and rheumatoid arthritis (NCT01575873).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis.’ (ABSTRACT NUMBER: 0445) was presented at the ACR Convergence, 3-9 November 2021.
Questions
- How common is the incidence of osteoporosis following glucocorticoid use in patients with rheumatoid arthritis? (0:14)
- What are the unmet needs in the treatment of glucocorticoid–induced osteoporosis? (0:48)
- What have phase 3 clinical trial data taught us about the efficacy and safety of denosumab compared with risedronate in the treatment of people with glucocorticoid–induced osteoporosis? (1:15)
- What were the aims of the recent post-hoc subgroup analysis? (1:53)
- What were the findings of this analysis? (2:14)
- What was the conclusion of the investigators in terms of denosumab use in RA patients continuing to receive glucocorticoids? (2:30)
Disclosures: Rick Adachi discloses consulting for Amgen and Gilead; Clinical Trials with Amgen and Radius; Speaker Bureau for Amgen and Gilead.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
